


Tenapanor

Chemical Properties

CAS No. :	1234423-95-0
Formula:	C50H66Cl4N8O10S2
Molecular Weight:	1145.05
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Tenapanor (RDX 5791) is an inhibitor of the sodium-proton (Na ⁺)/H ⁺) exchanger NHE3, which plays a prominent role in sodium handling in the gastrointestinal tract and kidney. Tenapanor possesses an excellent preclinical safety profile and, as of now, there are no serious concerns about its side effects.
Targets(IC50)	Sodium Channel

Solubility Information

Solubility	DMSO: 150 mg/mL (131 mM),Sonication is recommended. H2O: < 0.1 mg/mL (insoluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (1.75 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.8733 mL	4.3666 mL	8.7332 mL
5 mM	0.1747 mL	0.8733 mL	1.7466 mL
10 mM	0.0873 mL	0.4367 mL	0.8733 mL
50 mM	0.0175 mL	0.0873 mL	0.1747 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Johansson SA, Knutsson M, Leonsson-Zachrisson M, Rosenbaum DP. Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study. *Clin Pharmacol Drug Dev.* 2017 Mar 24. doi: 10.1002/cpdd.341. [Epub ahead of print] PubMed PMID: 28339149.
- Zhao L, Sun X, Hou C, et al. CPNE7 promotes colorectal tumorigenesis by interacting with NONO to initiate ZFP42 transcription. *Cell Death & Disease.* 2024, 15(12): 896.
- Johansson S, Rosenbaum DP, Ahlqvist M, Rollison H, Knutsson M, Stefansson B, Elebring M. Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions. *Clin Pharmacol Drug Dev.* 2017 Mar 16. doi: 10.1002/cpdd.346. [Epub ahead of print] PubMed PMID: 28301096.
- Chey WD, Lembo AJ, Rosenbaum DP. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial. *Am J Gastroenterol.* 2017 Feb 28. doi: 10.1038/ajg.2017.41. [Epub ahead of print] PubMed PMID: 28244495.
- Carney EF. Dialysis: Efficacy of tenapanor in hyperphosphataemia. *Nat Rev Nephrol.* 2017 Apr;13(4):194. doi: 10.1038/nrneph.2017.27. PubMed PMID: 28239171.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481